Impact News +++ How Applied Optoelectronics became the latest viral AI stock (MarketWatch) +++ APPLIED OPTOELECTRONICS Aktie -3,89%

IPSEN Aktie

>IPSEN Aktienkurs

166.5 EUR +1.3% (TradegateBSX)

Ask: 166.8 EUR / 7 Stück

Bid: 165.9 EUR / 7 Stück

Tagesumsatz: 284 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IPSEN Aktie über LYNX handeln

Intraday

1 Jahr

>IPSEN Performance

1 Woche: +4,5%

1 Monat: +18,5%

3 Monate: +31,9%

6 Monate: +40,9%

1 Jahr: +50,5%

laufendes Jahr: +36,9%

>IPSEN Aktie

Name:

IPSEN S.A. PORT. EO 1

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0010259150 / A0ESMG

Symbol/ Ticker:

I7G (Frankfurt)

Kürzel:

FRA:I7G, ETR:I7G, I7G:GR

Index:

Webseite:

https://www.ipsen.com/

Profil:

Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology..
>Volltext..

Marktkapitalisierung:

13633.43 Mio. EUR

Unternehmenswert:

13080.22 Mio. EUR

Umsatz:

3654.42 Mio. EUR

EBITDA:

1612.12 Mio. EUR

Nettogewinn:

440.91 Mio. EUR

Gewinn je Aktie:

5.33 EUR

Schulden:

964.83 Mio. EUR

Liquide Mittel:

1516.58 Mio. EUR

Operativer Cashflow:

1131.75 Mio. EUR

Bargeldquote:

1.06

Umsatzwachstum:

8.1%

Gewinnwachstum:

28.22%

Dividende je Aktie:

1.4 EUR

Dividendenrendite:

0.85%

Dividendenschätzung:

0.85%

Div. Historie:

04.06.25 - 1.4€
30.05.24 - 1.2€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

IPSEN

Letzte Datenerhebung:

02.03.26

>IPSEN Kennzahlen

Aktien/ Unternehmen:

Aktien: 82.71 Mio. St.

Frei handelbar: 41.73%

Leerverk. Aktien: -

Rückkaufquote: 0.49%

Mitarbeiter: 5535

Umsatz/Mitarb.: 0.66 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: -8.19%

Bewertung:

KGV: 29.33

KGV lG: 12.97

KUV: 3.42

KBV: 2.98

PEG-Ratio: 1.01

EV/EBITDA: 8.11

Rentabilität:

Bruttomarge: 72.38%

Gewinnmarge: 12.07%

Operative Marge: 27.11%

Managementeffizenz:

Gesamtkaprendite: 6.63%

Eigenkaprendite: 10.41%

>IPSEN Peer Group

Gesundheit, Nierenerkrankungen & -behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Onkologie/ Krebs- Behandlung

>IPSEN Chart & Kurs - Tradegate

>IPSEN News

27.02.26 - 12:24

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma (GlobeNewswire EN)

PARIS, FRANCE, 27 FEBRUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional marketing authorization of Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (pLGG) harbouring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.i...

27.02.26 - 12:12	Quotient and Ipsen extend partnership for ultra-rare disease therapy (PBR)
	FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes The post Quotient and Ipsen extend partnership for ultra-rare disease therapy appeared first on Pharmaceutical Business review....

26.02.26 - 15:03	Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment (PR Newswire)
	PHILADELPHIA , Feb. 26, 2026 /PRNewswire/ -- Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a......

25.02.26 - 16:03	Ellucian CEO Laura Ipsen Named 2026 CNBC Changemaker (PR Newswire)
	Key Highlights: CNBC Changemakers: Women Transforming Business annual list recognizes women leaders driving measurable impact across business and philanthropy. Ipsen was selected for purpose-driven leadership advancing technology innovation transforming higher education worldwide. Under......

19.02.26 - 10:27	Ipsen S.A. publishes its 2025 Consolidated Financial Statements (GlobeNewswire EN)
	Ipsen S.A. publishes its 2025 Consolidated Financial Statements...

12.02.26 - 20:00	Genfit adds $20M as Ipsen records strong sales for liver drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 18:39

GENFIT to receive US$20M milestone after Ipsen′s Iqirvo® exceeds the US$200M threshold in its first full year of net sales (GlobeNewswire EN)

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the strong commercial performance of Iqirvo® in its first full year on the primary biliary cholangitis (PBC) market has triggered a US$20M milestone payment from Ipsen under the companies' licensing agreement....

12.02.26 - 15:12	Ipsen übertrifft Prognosen in Q4 2025 – Aktie legt deutlich zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 09:15	Ipsen shares jump as 2026 guidance exceeds expectations (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 09:12	Ipsen Full-Year Profit Rises On Higher Sales; Sees Over 13% Sales Growth In 2026 (AFX)
	PARIS (dpa-AFX) - Ipsen S.A. (IPSEY), a specialty-care biopharmaceutical company, on Thursday reported higher earnings for 2025, supported by stronger sales performance.Net income attributable to ......

12.02.26 - 07:33	Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 07:03	Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance (GlobeNewswire EN)
	PARIS, FRANCE, 12 February 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year (FY) 2025 and for the fourth quarter of 2025....

09.02.26 - 18:33	Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
	Monthly information relative to the total number of voting rights and shares composing the share capital...

05.02.26 - 23:33	Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) \| DelveInsight (PR Newswire)
	According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025–2034), driven by the launch of emerging therapies such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen),......

29.01.26 - 07:03	Ipsen nominates Peter Guenter to its Board of Directors (GlobeNewswire EN)
	PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour's position....

27.01.26 - 07:03	Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team (GlobeNewswire EN)
	PARIS, FRANCE, 27 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan Murphy, EVP Technical Operations and Member of the ELT, who after 30 years of excellent service at Ipsen, will retire in March 2026....

22.01.26 - 08:54	Galderma und Ipsen beenden F&E-Partnerschaft für Neuromodulatoren nach Schiedsspruch (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

21.01.26 - 17:48

Arbitration tribunal upholds Ipsen′s termination of R&D agreement with Galderma (GlobeNewswire EN)

PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen's termination of the R&D agreement. The ICC Tribunal's decision confirms Ipsen's full rights to its clinical stage toxin programs in the aesthetic field....

14.01.26 - 13:00	Ipsen rises on FDA breakthrough therapy status for blood cancer therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.01.26 - 07:03

New data reinforces Ipsen′s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS (GlobeNewswire EN)

PARIS, FRANCE, 14 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14 across multiple neurological conditions at the TOXINS 2026 conference (14-17 January) in Madrid, Spain. Data presented highlighted the depth and diversity of evidence across multiple movement disorders — including post‑stroke spasticity, cervical dystonia and blepharospasm, adding to the available evidence of Dysport®(abobotulinumtoxinA) in patient care – alongside new indications under evaluation....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Eine schöne Frau gehört der Welt, eine häßliche dir allein. - Sprichwort Indien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram